Skip to content

Baxter International BAX Goodwill impairment

Discontinued — last reported Q4 '25

Goodwill impairment at other companies

Viatris logo
ViatrisVTRS
$0-100%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$41.25M-23.3%
Medtronic logo
MedtronicMDT

Segments

By product

See full
Front Line Care$485M+14.1%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$10.27B-50.6%
Enterprise value$8.48B-55.6%
P/S0.9×-1.0×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.

The official record: Baxter International’s 10-K, filed February 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's goodwill impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Baxter International's goodwill impairment?
Baxter International (BAX) reported goodwill impairment of $121.25M in Q4 2025.
What does goodwill impairment mean?
A write-down of the value of an acquired business when it is no longer worth what was originally paid.
How do you interpret goodwill impairment?
Frequent or large impairments signal poor capital allocation or overpayment for previous acquisitions, indicating potential strategic missteps.
How does goodwill impairment compare across companies?
Used by investors to evaluate the success of a company's M&A strategy compared to industry peers.